Mexiletine
- Atc Codes:C01BB02
- CAS Codes:5370-01-4#31828-71-4
- PHARMGKB ID:5370-01-4#31828-71-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Germany: Mexitil; Greece: Mexitil; Hungary: Ritalmex; Italy: Mexitil; Luxembourg: Mexitil; Malta: Mexitil; Netherlands: Mexitil; Poland: Katen, Mexicord, Mexitil; Romania: Mexitil; Sweden: Mexitil.
North America
Canada: Mexiletine; USA: Mexiletine.
Latin America
Brazil: Mexitil.
Asia
Japan: Cirumimeru, Mekiratin, Melate, Meldest, Mequitolide, Metorekicin, Mexibal, Mexirate, Mexitil, Mobalen, Olzoron, Poeruten, Toi.
Drug combinations
Chemistry
Mexiletine Hydrochloride: C~11~H~17~NO HCl. Mw: 215.72. (1) 2-Propanamine, 1-(2,6-dimethylphenoxy)-, hydrochloride, (±)-; (2)(±)-1-Methyl-2-(2,6-xylyloxy)ethylamine hydrochloride. CAS-5370-01-4; CAS-31828-71-4 (mexiletine)(1986).
Pharmacologic Category
Class Ib Antiarrhythmics. (ATC-Code: C01BB02).
Mechanism of action
Inhibits inward sodium current, decreases rate of rise of phase 0, increases effective refractory period/action potential duration ratio.
Therapeutic use
Management of serious ventricular arrhythmias. Suppression of premature ventricular contractions.
Pregnancy and lactiation implications
Use caution when administered during pregnancy or lactation.
Unlabeled use
Diabetic neuropathy.
Contraindications
Hypersensitivity to mexiletine or any component of the formulation. Cardiogenic shock. Second- or third-degree AV block (except in patients with a functioning artificial pacemaker).
Warnings and precautions
Rare hepatic toxicity may occur (might cause acute hepatic injury). Proarrhythmic effects possible. Use with caution in intraventricular conduction delays, first-degree heart block and/or pre-existing sinus node dysfunction. Electrolyte imbalance (hypokalemia or hypomagnesemia) possible. Use with caution in severe heart failure (might precipitate or exacerbate condition), in significant hepatic impairment, and in hypotension. Alterations in urinary pH may change urinary excretion.